Relevant bibliographies by topics / Phospholipid antibodies

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Phospholipid antibodies'

Author: Grafiati
Published: 4 June 2021
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Phospholipid antibodies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Phospholipid antibodies"

1

Out, HJ, PG de Groot, M. van Vliet, GC de Gast, HK Nieuwenhuis, and RH Derksen. "Antibodies to platelets in patients with anti-phospholipid antibodies." Blood 77, no. 12 (June 15, 1991): 2655–59. http://dx.doi.org/10.1182/blood.v77.12.2655.2655.

Full text
Abstract:
Abstract Binding of anti-phospholipid antibodies to circulating platelets and its consequences on platelet activation and aggregation was investigated in 11 patients with anti-phospholipid antibodies. Seven patients had mild thrombocytopenia. Nine healthy donors served as controls. Binding to platelets was investigated by performing enzyme- linked immunosorbent assays (ELISAs) with phospholipids as antigen on platelet eluates. Platelet activation was measured by flow cytofluorometry using monoclonal antibodies to an activation-specific lysosomal membrane protein. Findings in ELISA were compare
APA, Harvard, Vancouver, ISO, and other styles
2

Out, HJ, PG de Groot, M. van Vliet, GC de Gast, HK Nieuwenhuis, and RH Derksen. "Antibodies to platelets in patients with anti-phospholipid antibodies." Blood 77, no. 12 (June 15, 1991): 2655–59. http://dx.doi.org/10.1182/blood.v77.12.2655.bloodjournal77122655.

Full text
Abstract:
Binding of anti-phospholipid antibodies to circulating platelets and its consequences on platelet activation and aggregation was investigated in 11 patients with anti-phospholipid antibodies. Seven patients had mild thrombocytopenia. Nine healthy donors served as controls. Binding to platelets was investigated by performing enzyme- linked immunosorbent assays (ELISAs) with phospholipids as antigen on platelet eluates. Platelet activation was measured by flow cytofluorometry using monoclonal antibodies to an activation-specific lysosomal membrane protein. Findings in ELISA were compared with re
APA, Harvard, Vancouver, ISO, and other styles
3

Rauch, J., and AS Janoff. "Antibodies against Phospholipids other than Cardiolipin: Potential Roles for Both Phospholipid and Protein." Lupus 5, no. 5 (October 1996): 498–502. http://dx.doi.org/10.1177/096120339600500534.

Full text
Abstract:
Autoantibodies to phospholipids other than cardiolipin have received less attention, to date, than anti-cardiolipin antibodies. This review focuses on these antibodies and potential roles for both phospholipid and protein in their reactivity. We review data in the literature indicating that antibodies to phosphatidylethanolamine and some lupus anticoagulant antibodies recognize phospholipid-binding proteins in association with phospholipid. Kininogens appear to be involved in the binding of antibodies to phosphatidylethanolamine, while phosphatidylserine-binding proteins, such as prothrombin a
APA, Harvard, Vancouver, ISO, and other styles
4

Harris, EN, and SS Pierangeli. "Functional Effects of Anticardiolipin Antibodies." Lupus 5, no. 5 (October 1996): 372–77. http://dx.doi.org/10.1177/096120339600500507.

Full text
Abstract:
The ‘lupus anticoagulant’ phenomenon is the best documented functional effect of antiphospholipid (aPL) antibodies, occurring either by inhibition of the prothrombinase and/or Factor X activation reactions. Understanding the mechanism by which aPL antibodies inhibit phospholipid dependent coagulation reactions may yield important clues about their ‘thrombogenic effects’ in vivo. We conducted a series of studies to determine the specificity, diversity, and mechanism by which aPL antibodies inhibit phospholipid dependent reactions. Results showed that purified immunoglobulins with lupus anticoag
APA, Harvard, Vancouver, ISO, and other styles
5

BRIGHTON, Timothy A., Yan-Ping DAI, Philip J. HOGG, and Colin N. CHESTERMAN. "Microheterogeneity of beta-2 glycoprotein I: implications for binding to anionic phospholipids." Biochemical Journal 340, no. 1 (May 10, 1999): 59–67. http://dx.doi.org/10.1042/bj3400059.

Full text
Abstract:
Considerable interest is currently focused on the interactions of beta-2 glycoprotein I (β2GPI) and anti-phospholipid antibodies with anionic phospholipids in an attempt to understand the association between these antibodies and clinical diseases such as thrombosis. The interactions of β2GPI and anionic phospholipids have only been characterized partially, and the physiological role of this glycoprotein remains uncertain. In this study we have explored in detail the physical and phospholipid-binding characteristics of a number of β2GPI preparations. We have found (i) that perchloric acid-purif
APA, Harvard, Vancouver, ISO, and other styles
6

Harris, E. N., A. E. Gharavi, and G. R. V. Hughes. "Anti-phospholipid Antibodies." Clinics in Rheumatic Diseases 11, no. 3 (December 1985): 591–609. http://dx.doi.org/10.1016/s0307-742x(21)00606-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tincani, A., L. Andreoli, and Y. Shoenfeld. "Anti-phospholipid antibodies." Rheumatology 53, no. 2 (November 27, 2013): 201–2. http://dx.doi.org/10.1093/rheumatology/ket394.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Deegan, Michael J. "Anti-Phospholipid Antibodies." American Journal of Clinical Pathology 98, no. 4 (October 1, 1992): 390–91. http://dx.doi.org/10.1093/ajcp/98.4.390.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mackworth-Young, C. G. "Anti phospholipid antibodies." Current Opinion in Immunology 1, no. 4 (January 1988): 747–52. http://dx.doi.org/10.1016/0952-7915(89)90052-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Banerji, Benoy, and Carl R. Alving. "Antibodies to liposomal phosphatidylserine and phosphatidic acid." Biochemistry and Cell Biology 68, no. 1 (January 1, 1990): 96–101. http://dx.doi.org/10.1139/o90-012.

Full text
Abstract:
Polyclonal antisera to phosphatidylserine or phosphatidic acid were induced in rabbits by injecting liposomes containing phosphatidylserine or phosphatidic acid and lipid A. Adsorption of antisera with liposomes containing different phospholipids revealed that some degree of reactivity with one or more phospholipids other than the immunizing phospholipid was often observed. However, cross-reactivity with other phospholipids was not a universal phenomenon, and one antiserum to phosphatidylserine failed to cross-react (i.e., was not adsorbed) with liposomes containing other phospholipids. All of
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Phospholipid antibodies"

1

Kang, Sun-ah. "Apoptotic Cells, Anti-Phospholipid Antibodies, and Anti-Chromatin Antibodies in Autoimmunity." Diss., Temple University Libraries, 2008. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/15651.

Full text
Abstract:
Microbiology and Immunology<br>Ph.D.<br>Antiphospholipid antibodies (APAs) are detected in various autoimmune diseases, such as antiphospholipid syndrome (APS) and systemic lupus erythematosus. In addition to their binding to negatively charged phospholipids, APAs often cross-react with other molecules. Their potential biological effects are not fully understood. Apoptotic cells are a potential source of auto-antigens during systemic autoimmunity. Inefficient clearance of apoptotic cells results in the development of autoimmune manifestations and intracellular antigens such as nucleosomes
APA, Harvard, Vancouver, ISO, and other styles
2

Robinson, Cheryl. "The role of anti-phospholipid antibodies in pregnancy loss /." Thesis, McGill University, 2004. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=82414.

Full text
Abstract:
Recurrent pregnancy loss is associated with anti-phospholipid antibodies (aPL), in particular in women with anti-phospholipid syndrome. aPL are a large family of autoantibodies, directed against phospholipids and phospholipid-binding proteins (e.g., prothrombin and beta2-glycoprotein I). Although the association between aPL and recurrent pregnancy loss is well documented, little is known about which aPL subset is responsible. To address this, we characterized a panel of six murine monoclonal aPL, which were subsequently administered to pregnant mice via passive transfer. While both anti
APA, Harvard, Vancouver, ISO, and other styles
3

D'Agnillo, Paolo. "Characterization of the reactivity of prothrombin-dependent anti-phospholipid antibodies with apoptotic cells." Thesis, McGill University, 2001. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=32987.

Full text
Abstract:
Anti-phospholipid antibodies (aPL) occur in patients with the anti-phospholipid syndrome, and are directed against various combinations of phospholipids and phospholipid-binding proteins (e.g., beta2-glycoprotein I and prothrombin). Lupus anticoagulants (LA), a subset of aPL, exhibit anticoagulant properties in vitro, but are strikingly procoagulant in vivo. We have previously demonstrated that some aPL bind specifically to apoptotic, but not viable, thymocytes in the presence of beta2-glycoprotein 1. Here, we demonstrate that prothrombin binds selectively to the surface of apoptotic Jurkat ce
APA, Harvard, Vancouver, ISO, and other styles
4

Giannakopoulos, Bill Clinical School St George Hospital Faculty of Medicine UNSW. "Investigations on beta 2-glycoprotein I and antiphospholipid antibodies." Publisher:University of New South Wales. Clinical School - St George Hospital, 2008. http://handle.unsw.edu.au/1959.4/41440.

Full text
Abstract:
An outline of the work contained in this thesis is presented. The first chapter is a critical review of the literature pertaining to the pathophysiological mechanisms operational with regards to the antiphospholipid syndrome (APS). The syndrome is characterised by venous and arterial thrombosis, and recurrent fetal loss, in association with the persistent presence of antibodies targeting the main autoantigen beta 2-glycoprotein I (β2GPI). The second chapter reviews the literature delineating the diverse physiological functions of β2GPI, and then relates them to its role in our current understa
APA, Harvard, Vancouver, ISO, and other styles
5

Radway-Bright, Emma-Louise. "The pathogenic potential of the anti-phospholipid antibodies associated with the antiphospholid syndrome and systemic lupus erythematosus." Thesis, University College London (University of London), 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.270189.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gatenby, Paul, Gytis Danta, Roger Tuck, Colin Andrews, and Carolyn Hawkins. "Cerebrovascular disease associated with antiphospholipid antibodies: more questions than answers." Master's thesis, BioMed Central, 2006. http://hdl.handle.net/10440/104.

Full text
Abstract:
Neurological syndromes occur in a significant number of patients with antiphospholipid antibodies. The optimal management for these patients however remains uncertain. Our study is a descriptive analysis looking retrospectively at 45 patients who presented to the principal tertiary referral centre in the Australian Capital Territory, with either cerebral arterial or venous thrombosis for which there was no obvious cause for their presentation when initially reviewed. The diagnosis was based on the clinical findings made by one of three neurologists attached to our centre. Radiological fi
APA, Harvard, Vancouver, ISO, and other styles
7

Paavola, T. (Timo). "Associations of low HDL cholesterol level and premature coronary heart disease with functionality and phospholipid composition of HDL and with plasma oxLDL antibody levels." Doctoral thesis, Oulun yliopisto, 2019. http://urn.fi/urn:isbn:9789526223360.

Full text
Abstract:
Abstract Coronary heart disease (CHD) is a clinical manifestation of atherosclerosis. It is a major cause of mortality and morbidity both in Finland and globally. Even after the best known treatments a significant residual risk of CHD remains. A low plasma HDL cholesterol level (HDL, high-density lipoprotein) is a common lipid abnormality in patients affected by premature CHD and also a component of the metabolic syndrome, a cluster of risk factors for atherosclerosis associated with central obesity. In this study, a phenotype of low HDL cholesterol level and premature CHD was investigated in
APA, Harvard, Vancouver, ISO, and other styles
8

Nissinen, A. (Antti). "Humoral immune response to phosphatidylethanol." Doctoral thesis, Oulun yliopisto, 2011. http://urn.fi/urn:isbn:9789514295232.

Full text
Abstract:
Abstract Heavy alcohol consumption places a substantial burden on health all over the world. Metabolites of alcohol evoke alterations that lead to tissue damage in many organs. Phosphatidylethanol (PEth) is a unique phospholipid formed in the cellular membranes during the metabolism of ethanol after alcohol consumption. PEth has attracted special attention as it is postulated to be a reliable marker of long term heavy alcohol consumption. The aims of present study were to investigate the immunogenicity of phosphatidylethanol in mice and to analyze the plasma antibodies binding to phosphatidyle
APA, Harvard, Vancouver, ISO, and other styles
9

Bouvier, Sylvie. "Nouveaux acteurs moléculaires de la dysfonction vasculo-placentaire." Thesis, Montpellier 1, 2014. http://www.theses.fr/2014MON13505.

Full text
Abstract:
La grossesse est une période de majoration du risque vasculaire, participant à une morbi-mortalité maternelle et fœtale pouvant justifier des mesures de prévention primaire et secondaire. Notre travail évalue l'impact de certains déterminants et l'apport de nouveaux acteurs moléculaires impliqués dans la dysfonction vasculo-placentaire. Le but ultime étant d'optimiser les prises en charge et de développer de nouvelles stratégies thérapeutiques. Nous avons étudié les complications vasculaires placentaires associées à des marqueurs biologiques connus : mutation du facteur V Leiden, mutation du g
APA, Harvard, Vancouver, ISO, and other styles
10

Ju, Cheng, and 鄭儒. "The study of human parvovirus B19 infection and anti-phospholipid antibodies." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/51656287136227222383.

Full text
Abstract:
碩士<br>中山醫學大學<br>生化微生物免疫研究所<br>104<br>Human parvovirus B19 (B19) is classified as Parvoviridae family and known causing disease in humans. The virus capsid is composed of two structural proteins, VP1 and VP2, which are identical except for 227 amino acids at the amino-terminal end of the VP1-protein, the so-called VP1-unique region (VP1u). B19-VP1u proteins have secretary phospholipase A2 (sPLA2) activity, which is essential for viral infectivity and as the region to neutralize the immune response (VP1u-IgG). Previous studies show B19-VP1u induces the production of anti-phospholipid antibody. T
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Phospholipid antibodies"

1

Nigel, Harris E., ed. Phospholipid-binding antibodies. Boca Raton: CRC Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Immunophysiology of antiphospholipid antibodies. Austin: R.G. Landes, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Asherson, Ronald A., Graham R. V. Hughes, E. Nigel Harris, and Thomas Exner. Phospholipid-Binding Antibodies. Taylor & Francis Group, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Asherson, Ronald A., Graham R. V. Hughes, E. Nigel Harris, and Thomas Exner. Phospholipid-Binding Antibodies. Taylor & Francis Group, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Phospholipid-Binding Antibodies. Taylor & Francis Group, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Harris, E. Nigel, Thomas Exner, Graham R. V. Hughes, and Ronald A. Asherson. Phospholipid-Binding Antibodies. Edited by E. Nigel Harris, Thomas Exner, Graham R. V. Hughes, and Ronald A. Asherson. CRC Press, 2020. http://dx.doi.org/10.1201/9780429278129.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Asherson, Ronald A., Graham R. V. Hughes, E. Nigel Harris, and Thomas Exner. Phospholipid-Binding Antibodies. Taylor & Francis Group, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Asherson, Ronald A., Graham R. V. Hughes, E. Nigel Harris, and Thomas Exner. Phospholipid-Binding Antibodies. Taylor & Francis Group, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Khamashta, Munther A., Graham R. V. Hughes, and Guillermo Ruiz-Irastorza. Anti-phospholipid antibody syndrome. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0120.

Full text
Abstract:
The anti-phospholipid syndrome (APS) described almost 30 years ago, is now recognized as a major cause of deep vein thrombosis, stroke, and heart attacks in young people (&lt;45 years of age). It is also the commonest treatable cause of recurrent miscarriages and a major cause of late fetal death. Other clinical manifestations are cardiac valvular disease, livedo reticularis, renal thrombotic microangiopathy, thrombocytopenia, haemolytic anaemia, epilepsy, and cognitive impairment. The presence of anti-phospholipid antibodies (aPL) has been closely related to the development of thrombosis and
APA, Harvard, Vancouver, ISO, and other styles
10

Khamashta, Munther A., Graham R. V. Hughes, and Guillermo Ruiz-Irastorza. Anti-phospholipid antibody syndrome. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199642489.003.0120_update_001.

Full text
Abstract:
The anti-phospholipid syndrome (APS) described almost 30 years ago, is now recognized as a major cause of deep vein thrombosis, stroke, and heart attacks in young people (&lt;45 years of age). It is also the commonest treatable cause of recurrent miscarriages and a major cause of late fetal death. Other clinical manifestations are cardiac valvular disease, livedo reticularis, renal thrombotic microangiopathy, thrombocytopenia, haemolytic anaemia, epilepsy, and cognitive impairment. The presence of anti-phospholipid antibodies (aPL) has been closely related to the development of thrombosis and
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Phospholipid antibodies"

1

Harris, E. N. "Clinical and immunological significance of anti-phospholipid antibodies." In Early Pregnancy Loss, 43–60. London: Springer London, 1988. http://dx.doi.org/10.1007/978-1-4471-1658-5_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Miesbach, W., J. Vogt, D. Peez, Th Vigh, B. Bühler, G. Ashmelash, and I. Scharrer. "Factor V Inhibitor and Anti-Phospholipid Antibodies after Treatment with Ciprofloxacin." In 32nd Hemophilia Symposium Hamburg 2001, 123–26. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-18150-4_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Diener, W., R. Klein, K. Kast, U. Danneberg, M. Mohrmann, P. A. Berg, S. A. Dambinova, and R. Korinthenberg. "Increased Incidence of CNS- and Phospholipid Antibodies in Epileptic Syndromes of Childhood." In Neurochemistry, 281–86. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4615-5405-9_46.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Exner, Thomas, and Douglas Triplett. "Lupus Anticoagulants: Characteristics, Methods of Laboratory Detection and Some Clinical Associations." In Phospholipid-Binding Antibodies, 141–58. CRC Press, 2020. http://dx.doi.org/10.1201/9780429278129-11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Exner, Thomas, and David Green. "Acquired Circulating Anticoagulants Other than Lupus Anticoagulants." In Phospholipid-Binding Antibodies, 159–74. CRC Press, 2020. http://dx.doi.org/10.1201/9780429278129-12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Harris, E. N., A. E. Gharavi, and G. R. V. Hughes. "The Anti-Cardiolipin Assay." In Phospholipid-Binding Antibodies, 175–87. CRC Press, 2020. http://dx.doi.org/10.1201/9780429278129-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

McNeil, H. Patrick, Steven A. Krilis, and Colin N. Chesterman. "Arterial Thrombosis—Diagnosis and Management." In Phospholipid-Binding Antibodies, 191–203. CRC Press, 2020. http://dx.doi.org/10.1201/9780429278129-15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Stormorken, Helge. "Spontaneous (Unexplained) Thrombosis: The Inherited Basis for the Thrombohemorrhagic Balance." In Phospholipid-Binding Antibodies, 205–17. CRC Press, 2020. http://dx.doi.org/10.1201/9780429278129-16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Derksen, R. H. W. M., P. Hasselaar, and Ph G. de Groot. "The Pathogenetic Role of Anti-Phospholipid Antibodies in Thrombosis." In Phospholipid-Binding Antibodies, 219–30. CRC Press, 2020. http://dx.doi.org/10.1201/9780429278129-17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Carreras, Luis O., and Jos Vermylen. "Anti-Phospholipid Antibodies and Impairment of Prostacyclin Synthesis by the Endothelium." In Phospholipid-Binding Antibodies, 231–45. CRC Press, 2020. http://dx.doi.org/10.1201/9780429278129-18.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Phospholipid antibodies"

1

Triplett, D. A., J. T. Brant, K. Musgrave, and C. A. Orr. "RELATIONSHIP BETWEEN LUPUS ANTICOAGULANTS AND ANTIBODIES TO PHOSPHOLIPID." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643657.

Full text
Abstract:
The relationship of lupus anticoagulants (LA's) to antibodies (IgG and IgM) to cardiolipin (CL), phosphatidylserine (PS), phosphatidylinositol (PI) and phosphatidic acid (PA), detected by an enzyme linked immunoassay, was examined in a series of 100 patients with well characterized LA's. 73% of patients demonstrated antibodies to one or more phospholipids; 62% were positive for CL, 57% were positive for PS, 57% were positive for PI, and 51% were positive for PA. Of the samples with antibodies to phospholipid, 32% had IgG type antibody only, 16% had IgMonly, and 52% had both IgG and IgM antibod
APA, Harvard, Vancouver, ISO, and other styles
2

Cucnik, Sasa. "SP0176 PATHOGENIC ANTIBODIES IN PHOSPHOLIPID SYNDROM." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.8453.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dhir, V., A. Gawalkar, J. Ahluwalia, A. Bahl, S. Sharma, A. Sharma, and S. Jain. "AB0635 Anti-phospholipid antibodies in lupus myocarditis." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.3672.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Li, C., L. Zhu, Z. Wang, Y. Sun, R. Mu, and Z. Li. "AB0559 The prevalence of non-criteria anti-phospholipid antibodies in anti-phospholipid syndrome." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.6750.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Brien, W., G. Denome, and B. O’Keefe. "THE PREVELANCE OF ANTIPHOSPHOLIPID ANTIBODIES, BY ELISA TECHNIQUE, IN PATIENTS WITH THE LUPUS ANTICOAGULANT." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644234.

Full text
Abstract:
Patients with the Lupus Anticoagulant and/or anticardiolipin antibodies have been reported to be at increased risk of thrombosis and miscarriages. It has been proposed that the lupus anticoagulant is an antiphospholipid antibody.We evaluated 16 patients with the lupus anticoagulant for the presence of antiphospholipid antibodies. The lupus anticoagulant was documented by the presence of an abnormal APTT, abnormal mixing studies, positive tissue thromboplastin inhibition test and positive platelet neutralization test.Plasma from each patient was assessed for the presence of anticardiolipin, ant
APA, Harvard, Vancouver, ISO, and other styles
6

Harris, EN, G. Wasley, and GRV Hughes. "DISTINCTION BETWEEN ANTI CARDIOLIPIN (aCL) ANTIBODIES IN SYPHLIS AND THE "ANTI PHOSPHOLIPID SYNDROME"." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643658.

Full text
Abstract:
Patients both with syphilis and with the Anti-Phospholipid Syndrome (APS) produce antibodies that bind cardiolipin (CL). However, thrombosis, fetal loss, and thrombocytopenia, as well as lupus anticoagulant (LA) activity occur in APS but not syphilis patients. Differences between aCL antibodies produced in these 2 disorders have been suggested but not proven. We report a newly devised ELI9A assay using carbon coated VDRL (C-VDRL) as antigen, as well as a variety of other ELISA assays with various phospholipids as antigens, to study sera from 20 syphilis and 10 APS patients. Inhibition experime
APA, Harvard, Vancouver, ISO, and other styles
7

Chighizola, C. B., F. Pregnolato, M. G. Raimondo, C. Comerio, C. Sobrino Grande, L. Trespidi, M. O. Borghi, et al. "FRI0349 Low titer anti-phospholipid antibodies convey an increased obstetric risk." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5887.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Pengo, V., M. J. Heine, P. Thiagarajan, and s. s. Shapiro. "A GENERAL MECHANISM FOR LUPUS ANTICOAGULANTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643660.

Full text
Abstract:
Although- a number of observations have implied that lupus anticoagulants have immunologic specificity towards anionic. phospholipids, thereby prolonging phospholipid-dependent coagulation tests, this assumption has been directly demonstrated in only one patient with a monoclonal IgM paraprotein. We have tested the generality of this hypothesis directly by isolating five IgG lupus anticoagulants from patients with lupus-like syndromes and/or thrombosis. IgG lupus anticoagulant fractions were isolated free of other plasma proteins and free of contaminating phospholipid by adsorption to and elut
APA, Harvard, Vancouver, ISO, and other styles
9

Ince, A., A. Roumany, U. Daud, PH Pepmueller, and TL Moore. "FRI0172 Long-term follow-up of paediatric patients with positive anti-phospholipid antibodies." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.241.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Day, Cameron, and Paul Neilsen. "Abstract 4601: Phospholipid and enzyme antibodies for the evaluation of novel cancer biomarkers." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4601.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Phospholipid antibodies' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography